1. Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting

2. Sarcoma Highlights: Presented By Dennis Priebat at 2014 ASCO Annual Meeting

3. Long-term Disease Control of Advanced Gastrointestinal Stromal Tumors (GIST) with Imatinib (IM): 10-year Outcomes from SWOG Phase III Intergroup Trial S0033 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

4. S0033 Study Design: Randomized Phase III trial of Imatinib at 400 vs. 800 mg/d for Advanced KIT-expressing GIST Presented By Dennis Priebat at 2014 ASCO Annual Meeting

5. S0033 Long-Term Study Events Presented By Dennis Priebat at 2014 ASCO Annual Meeting

6. Slide 6 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

7. Analysis of On-Study and Post-Progression Therapies (i.e. after progression on imatinib) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

8. Analysis of Post-Progression Therapies (i.e. after progression on imatinib) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

9. Summary S0033: Presented By Dennis Priebat at 2014 ASCO Annual Meeting

10. Summary S0033: Presented By Dennis Priebat at 2014 ASCO Annual Meeting

11. Unmet Treatment Challenges for the Expanding GIST Landscape Presented By Dennis Priebat at 2014 ASCO Annual Meeting

12. AngioTax-Plus trial: a randomized phase II trial assessing the activity of weekly paclitaxel (WP) +/- bevacizumab (B) in advanced angiosarcoma (AS) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

13. Angiosarcoma Presented By Dennis Priebat at 2014 ASCO Annual Meeting

14. Patients & methods Presented By Dennis Priebat at 2014 ASCO Annual Meeting

15. Treatments Presented By Dennis Priebat at 2014 ASCO Annual Meeting

16. Baseline characteristics Presented By Dennis Priebat at 2014 ASCO Annual Meeting

17. Activity - Efficacy endpoints Presented By Dennis Priebat at 2014 ASCO Annual Meeting

18. Grade 3/4 Toxicities Presented By Dennis Priebat at 2014 ASCO Annual Meeting

19. Drug-related SAE Presented By Dennis Priebat at 2014 ASCO Annual Meeting

20. Summary Presented By Dennis Priebat at 2014 ASCO Annual Meeting

21. Proof of Concept Trials for Patients With Advanced Pigmented Villonodular Synovitis(PVNS): Presented By Dennis Priebat at 2014 ASCO Annual Meeting

22. Pigmented Villonodular Synovitis (PVNS) Tenosynovial Giant Cell Tumor (TGCT) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

23. Pigmented Villonodular Synovitis (PVNS) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

24. A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

25. Study Design Presented By Dennis Priebat at 2014 ASCO Annual Meeting

26. Patient Characteristics: Safety Population (n=23) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

27. Duration of Treatment (DOT), April 2014 data cutoff: Median 256 days (range 21-585 days) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

28. Tumor Volume Score (TVS) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

29. PLX3397 Clinical Efficacy in PVNS Rapid and Sustained Tumor Size Reductions in Most Cases Presented By Dennis Priebat at 2014 ASCO Annual Meeting

30. PLX3397 Clinical Efficacy in PVNS Presented By Dennis Priebat at 2014 ASCO Annual Meeting

31. Safety: PVNS Expansion Cohort AEs n = 23 Safety Population Presented By Dennis Priebat at 2014 ASCO Annual Meeting

32. Treatment-Related AEs ≥ Grade 3 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

33. Slide 33 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

34. Slide 34 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

35. Slide 35 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

36. Slide 36 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

37. Slide 37 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

38. Slide 38 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

39. Slide 39 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

40. CSF1R TKI or moAb for PVNS Presented By Dennis Priebat at 2014 ASCO Annual Meeting

41. CSF1R TKI or moAb for PVNS Presented By Dennis Priebat at 2014 ASCO Annual Meeting

42. Take Home Points Presented By Dennis Priebat at 2014 ASCO Annual Meeting